Optimized Method development and validation By QBD-Based Liquid Chromatographic Method For Estimation Of Molnupiravir
DOI:
https://doi.org/10.52783/jns.v14.2232Keywords:
Green assessment, Molnupiravir, Method Validation, QBD, Stability testingAbstract
mplementation of quality by design (QbD) in developing greener analytical methods provides valuable knowledge about the use of greener chemicals and their impact on method performance.Green analytical chemistry(GAC) has mainly focussed on developing analytical methods that are safe for the environment and the analyst. The GAC works on 12 principles that mainly focus on reducing solvent usage, replacing toxic chemicals, reusing the generated waste, and avoiding unnecessary steps.The prime focus of the existing study was to develop analytical quality by design aided stability indicating green high performance liquid chromatography(HPLC) method for estimationof Molnupiravir in a capsule dosage form. The critical chromatographic factors were the % of ethanol inthe mobile phase, and flow rate, their overall effect on the responses like capacity factor, tailing factor and theoreticalplates were studied to optimize the method. A rotatable central composite design was employed, and the optimized conditions for chromatographic separation were made with a run time of 10 minutes using Zorbax C18 column (4.6× 150 mm, 5 µm) with 0.1%acetic acid and ethanol (70:30 v/v) as components of a mobile phase, flowing ata rate of 1.0 ml/minute. Photodiode array detection was carried out at 235 nm..The retention time was found to be 4.21 min. According to the ICH guidlines, the proposedmethod was validated and stress studies revealed that Molnupiravir is prone to acidic and basic stress conditions. An analytical eco-scale score evaluated the greenness profile, and a software-based evaluation Analytical Greenness metrics, which affirmed excellent greenness. The developed HPLC method is more eco-friendly and shall be adoptedin the routine quality control of Molnupiravir in a capsule dosage form
Downloads
Metrics
References
Toots,M.,Yoon,J.J., Hart,M., Natchus, M.G.,Natchus,M.G.,Painter,G.R., Plemper, R.K. (2020) Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. Translational Research.2020;218:16–
doi:10.1016/j.trsl.2019.12.002
Painter ,W.P., Holman ,W., Bush ,J.A., Almazedi, F., Malik, H., Eraut, N.C..(2021) Human safety, tolerability, and pharmacokinetics of Molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-
Antimicrobial Agents and Chemotherapy. 2021; 65 (5). doi:10.1128 /AAC. 02428-20
Hampton T(2020) New flu antiviral candidate may thwart drug resistance. JAMA. 2020;323(1):17. doi: 10.1001/jama.2019.20225
Parmar B, Raj ,A., Chauhan ,D., Vasava, A., Chauhan,V., Dalwadi, M. and Upadhyay, U.(2022) UV visible spectroscopy method devlopment and validation for estimation of Molnupiravir in solid dosage form.International Journal of Creative Research Thoughts. 2022;10(4):d812-d821
Ahmed H. Abdelazim, Mohammed AS(2023) Abourehab,b,c Lobna M. Abd Elhalim,d Ahmed A. Almrasy,a and Sherif Ramzy,Green adherent spectrophotometric determination of Molnupiravir based on computational calculations; application to a recently FDA-approved pharmaceutical dosage form,Spectrochim Acta A Mol Biomol Spectrosc.2023; 285: 121911. doi: 10. 1016/j.saa.2022.121911
Saraya ,R.E., Deeb, S.E.I., Salman, B.I., Ibrahim,A.E. (2022) Highly sensitive high-performance thin-layer chromatography method for the simultaneous determination of Molnupiravir, Molnupiravir, and ritonavir in pure forms and pharmaceutical formulations.Journal of separation science.2022; 45(14), 2582-2590 https: //doi.org /10.1002
/jssc.202200178
Tekade ,M., Patil, P.(2022) Stability Indicating HPTLC Method of Molnupiravir and Comparative Study of Degradant with Marketed Molnupiravir Impurity- A. Iranian Journal of Analytical Chemistry.2022;9(2): 51-57. doi: 10.30473/ijac.2022.64848.1241
Amara A, Penchala SD, Else L, et al.(2021) The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite ß-d-N4-hydroxycytidine in human plasma and saliva. Journal of pharmaceutical and biomedical analysis.2021; 206: 114356. https://doi: 10.1016/ j.jpba. 2021.114356
Jain S, Giri S, Sharma N, Shah RP (2022) LC and LC-HRMS studies on stability behavior of Molnupiravir an anti- COVID 19 drug. Journal of Liquid Chromatography & Related Technologies.2022: 1-10. doi: https:// doi .org/10.1080/10826076.2022. 2063331
Bindu M., Gandla K, Vemireddy S, et al(2022) A validated stability indicating RP-HPLC method for the determination of Molnupiravir in pharmaceutical dosage form.. World Journal of Advanced Research and Reviews.2022;15(01): 580– 590
Camlik G, Beyazasla F, Kara E, et al.(2022) A validated high-pressure liquid chromatography (HPLC) method for Molnupiravir. Medical Research Archives.2022;10(9) :1-9 https://doi.org/10.18103/mra.v10i9.3127.
Amaranths G, Gandla KS, Repudi L(2023) New analytical method development and validation for estimation of Molnupiravir in bulk and capsule dosage form by RP-HPLC method. Cellular, Molecular and Biomedical Reports.2023; 3 (3): 130-136. doi: 10.55705/ cmbr.2023.375093.1087
Kalpana RM, Chaitanya SKP(2022) Sareesh K ,Analytical method development and validation for the estimation of Molnupiravir in bulk and pharmaceutical capsule dosage form by RPHPLC .International journal of Pharmacy and Pharmaceutical research.2022; 25 (4): 208-220.
Somshetwar K , Damle M(2022) Stability Indicating Eco-Friendly HPLC Method for Molnupiravir. International Journal of Science and Research.2022 ;11(3): 375-378, DOI: 10.21275/SR22307172002
Annadia ,A.M., Zaharbc, N.M., Nour ,D.A., Mohamed, E.H., Mahmoud ,S.A. and Attia,M.S. (2022) Development and validation of Molnupiravir assessment in bulk powder and pharmaceutical formulation by the RP-HPLC-UV method .RSC Adv.2022;12: 34512-34519, DOI: 10.1039/D2RA05066H
Reçber ,T, Timur, S.S., Kablan, S.E., Yalçın, F., Karabulut, T.C. (2022) A stability indicating RP-HPLC method for determination of the COVID-19 drug Molnupiravir applied using nanoformulations in permeability studies. Journal of pharmaceutical and biomedical analysis.2022; 214: 114693. https:// doi.org/ 10.1056/ EVIDoa2100043
Deshpande, M., Shaikh ,F., Sable ,V., Khushabu Patil, K., Holam,M.,R.,Tare,H.(2023) New stability indicating rp-hplc method for estimation of the drug Molnupiravir ,Internattional journal of Pharmaceutical Quality Assurance.2023;14(1):149-158
Sharaf, Y.A., Deeb, E., S., Ibrahim ,A.E.,Al-Harrasi, A., Sayed, R.A.(2022) Two green micellar HPLC and mathematically assisted UV spectroscopic methods for the simultaneous determination of Molnupiravir and Molnupiravir as a novel combined COVID-19 antiviral regimen.. Molecules.2022;27(7):2330.
Masipogu ,A. , Dodle, J., Anisett, R.(2022) stability indicating method development and method validation for the estimation of Molnupiravir in bulk and pharmaceutical dosage preparations by RP-UPLC. Indo american journal of pharmaceutical sciences .2022; 9 (10): 301-309
Rele, R.V., Tiwatane, P.P.(2022) determination of Molnupiravir by extractive colorimetric method from pharmaceutical dosage form. Asian Journal of Research in Chemistry.2022;15(4):256-8. doi: 10.52711/0974-4150.2022.00046
Sajid ,M.,Wasylka, J.P.(2022) Green analytical chemistry metrics: A review. Talanta .2022; 238: 123046. https:// doi.org/ 10.1016/ j.talanta. 2021. 123046
Pena-pereira, F, Wand ,W., Tobiszewski, M.(2020) AGREE—analytical greenness metric approach and software. Anal. Chem.2020; 92: 10076–10082 . https:// doi.org/ 10.1021/ acs. analchem.0c01887
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
